NorthStar Medical Radioisotopes, LLC (“NorthStar”), a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Alpha-9 Oncology Inc. (“Alpha-9”), a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals for treatment of a range of cancers, today announced a long-term strategic supply agreement for NorthStar to provide Alpha-9 with its non-carrier added (n.c.a.) Ac-225 for use in its development and clinical programs.
“NorthStar, using its advanced, proprietary electron accelerator technology, is on schedule to be one of the first commercial-scale producers of n.c.a. Ac-225. The n.c.a. Ac-225 we produce is free of long-lived radioactive contaminants and byproducts associated with other production methods – contaminants that pose regulatory and waste management challenges for pharmaceutical companies, hospitals, and health systems,” said Frank Scholz, Ph.D., Chief Executive Officer of NorthStar Medical Radioisotopes. “NorthStar’s advanced technology and expertise in isotope production will accelerate Alpha-9’s ability to advance a number of innovative, specialized radiopharmaceuticals to benefit patients with solid tumors and a variety of blood cancers while minimizing unwanted off-target effects. Working together, we believe NorthStar and Alpha-9 have the opportunity to make a difference for patients with serious disease.”
“The Alpha-9 team is well positioned to progress multiple targets into the clinic,” said David Hirsch, MD, Ph.D., Chief Executive Officer of Alpha-9 Oncology. “Robust supply of high-quality Ac-225 will help us advance a new generation of highly effective radiopharmaceuticals with improved tumor uptake and limited off-target exposure. We look forward to working with NorthStar and bringing our molecules to patients.”
About Alpha-9 Oncology, Inc. (Alpha-9)
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. For more information, please visit www.a9oncology.com.
About NorthStar Medical Radioisotopes, LLC (NorthStar)
NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases. NorthStar’s expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar routinely produces copper-67 (Cu-67) and is poised to be the first commercial-scale producer of non-carrier-added (n.c.a.) actinium-225 (Ac-225). The Company’s Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. For more information about NorthStar’s comprehensive portfolio and patient-focused services, visit: www.northstarnm.com.
